Stephan C A Wens1, Gerben J Schaaf1, Michelle Michels1, Michelle E Kruijshaar1, Tom J M van Gestel1, Stijn In 't Groen1, Joon Pijnenburg1, Dick H W Dekkers1, Jeroen A A Demmers1, Lex B Verdijk1, Esther Brusse1, Ron H N van Schaik1, Ans T van der Ploeg1, Pieter A van Doorn2, W W M Pim Pijnappel2. 1. From the Department of Neurology (S.C.A.W., E.B., P.A.v.D.), Center for Lysosomal and Metabolic Diseases (S.C.A.W., G.J.S., M.E.K., T.J.M.v.G., S.G., J.P., E.B., A.T.v.d.P., P.A.v.D., W.W.M.P.P.), Molecular Stem Cell Biology, Department of Clinical Genetics (G.J.S., T.J.M.v.G., S.G., J.P., W.W.M.P.P.), Department of Cardiology (M.M.), Department of Clinical Chemistry (R.H.N.v.S.), Erasmus MC University Medical Center, Rotterdam, The Netherlands; Division of Metabolic Diseases and Genetics, Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands (G.J.S., T.J.M.v.G., S.G., J.P., A.T.v.d.P., W.W.M.P.P.); Proteomics Center, Erasmus MC University Medical Center, Rotterdam, The Netherlands (D.H.W.D., J.A.A.D.); Netherlands Proteomics Center, Rotterdam, The Netherlands (D.H.W.D., J.A.A.D.); and NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands (L.B.V.). 2. From the Department of Neurology (S.C.A.W., E.B., P.A.v.D.), Center for Lysosomal and Metabolic Diseases (S.C.A.W., G.J.S., M.E.K., T.J.M.v.G., S.G., J.P., E.B., A.T.v.d.P., P.A.v.D., W.W.M.P.P.), Molecular Stem Cell Biology, Department of Clinical Genetics (G.J.S., T.J.M.v.G., S.G., J.P., W.W.M.P.P.), Department of Cardiology (M.M.), Department of Clinical Chemistry (R.H.N.v.S.), Erasmus MC University Medical Center, Rotterdam, The Netherlands; Division of Metabolic Diseases and Genetics, Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands (G.J.S., T.J.M.v.G., S.G., J.P., A.T.v.d.P., W.W.M.P.P.); Proteomics Center, Erasmus MC University Medical Center, Rotterdam, The Netherlands (D.H.W.D., J.A.A.D.); Netherlands Proteomics Center, Rotterdam, The Netherlands (D.H.W.D., J.A.A.D.); and NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands (L.B.V.). w.pijnappel@erasmusmc.nl p.a.vandoorn@erasmusmc.nl.
Abstract
BACKGROUND: Elevated plasma cardiac troponin T (cTnT) levels in patients with neuromuscular disorders may erroneously lead to the diagnosis of acute myocardial infarction or myocardial injury. METHODS AND RESULTS: In 122 patients with Pompe disease, the relationship between cTnT, cardiac troponin I, creatine kinase (CK), CK-myocardial band levels, and skeletal muscle damage was assessed. ECG and echocardiography were used to evaluate possible cardiac disease. Patients were divided into classic infantile, childhood-onset, and adult-onset patients. cTnT levels were elevated in 82% of patients (median 27 ng/L, normal values <14 ng/L). Cardiac troponin I levels were normal in all patients, whereas CK-myocardial band levels were increased in 59% of patients. cTnT levels correlated with CK levels in all 3 subgroups (P<0.001). None of the abnormal ECGs recorded in 21 patients were indicative of acute myocardial infarction, and there were no differences in cTnT levels between patients with and without (n=90) abnormalities on ECG (median 28 ng/L in both groups). The median left ventricular mass index measured with echocardiography was normal in all the 3 subgroups. cTnT mRNA expression in skeletal muscle was not detectable in controls but was strongly induced in patients with Pompe disease. cTnT protein was identified by mass spectrometry in patient-derived skeletal muscle tissue. CONCLUSIONS: Elevated plasma cTnT levels in patients with Pompe disease are associated with skeletal muscle damage, rather than acute myocardial injury. Increased cTnT levels in Pompe disease and likely other neuromuscular disorders should be interpreted with caution to avoid unnecessary cardiac interventions.
BACKGROUND: Elevated plasma cardiac troponin T (cTnT) levels in patients with neuromuscular disorders may erroneously lead to the diagnosis of acute myocardial infarction or myocardial injury. METHODS AND RESULTS: In 122 patients with Pompe disease, the relationship between cTnT, cardiac troponin I, creatine kinase (CK), CK-myocardial band levels, and skeletal muscle damage was assessed. ECG and echocardiography were used to evaluate possible cardiac disease. Patients were divided into classic infantile, childhood-onset, and adult-onset patients. cTnT levels were elevated in 82% of patients (median 27 ng/L, normal values <14 ng/L). Cardiac troponin I levels were normal in all patients, whereas CK-myocardial band levels were increased in 59% of patients. cTnT levels correlated with CK levels in all 3 subgroups (P<0.001). None of the abnormal ECGs recorded in 21 patients were indicative of acute myocardial infarction, and there were no differences in cTnT levels between patients with and without (n=90) abnormalities on ECG (median 28 ng/L in both groups). The median left ventricular mass index measured with echocardiography was normal in all the 3 subgroups. cTnT mRNA expression in skeletal muscle was not detectable in controls but was strongly induced in patients with Pompe disease. cTnT protein was identified by mass spectrometry in patient-derived skeletal muscle tissue. CONCLUSIONS: Elevated plasma cTnT levels in patients with Pompe disease are associated with skeletal muscle damage, rather than acute myocardial injury. Increased cTnT levels in Pompe disease and likely other neuromuscular disorders should be interpreted with caution to avoid unnecessary cardiac interventions.
Authors: Douwe de Boer; Alexander S Streng; William P T M van Doorn; Wim H M Vroemen; Otto Bekers; Will K W H Wodzig; Alma M A Mingels Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: R M Bell; M Basalay; H E Bøtker; S Beikoghli Kalkhoran; R D Carr; J Cunningham; S M Davidson; T J England; S Giesz; A K Ghosh; P Golforoush; A V Gourine; D J Hausenloy; G Heusch; B Ibanez; P Kleinbongard; S Lecour; K Lukhna; M Ntsekhe; M Ovize; A D Salama; G Vilahur; J M Walker; D M Yellon Journal: Basic Res Cardiol Date: 2022-08-15 Impact factor: 12.416
Authors: Erik van der Wal; Atze J Bergsma; Tom J M van Gestel; Stijn L M In 't Groen; Holm Zaehres; Marcos J Araúzo-Bravo; Hans R Schöler; Ans T van der Ploeg; W W M Pim Pijnappel Journal: Mol Ther Nucleic Acids Date: 2017-03-14
Authors: Paul Welsh; David Preiss; Caroline Hayward; Anoop S V Shah; David McAllister; Andrew Briggs; Charles Boachie; Alex McConnachie; Sandosh Padmanabhan; Claire Welsh; Mark Woodward; Archie Campbell; David Porteous; Nicholas L Mills; Naveed Sattar Journal: Circulation Date: 2019-04-24 Impact factor: 29.690
Authors: Atze J Bergsma; Stijn Lm In 't Groen; Frans W Verheijen; Ans T van der Ploeg; W W M Pim Pijnappel Journal: Mol Ther Nucleic Acids Date: 2016-09-13 Impact factor: 10.183